Antineoplastic agents 1998

被引：11
作者：
Menta, E
Palumbo, M
机构：
[1] Univ Padua, Dept Pharmaceut Sci, I-35131 Padua, Italy
[2] Boehringer Mannheim Italia, Res Ctr, I-20052 Monza, Italy
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 12期
关键词：
antimitotic agents; antimetabolites; apoptosis; DNA-targeted drugs; enzymatic inhibitors; hormone therapy; multi-drug resistance; photodynamic therapy;
D O I：
10.1517/13543776.8.12.1627
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
This review will focus on the most recent patent-disclosed advances in identifying new potent drugs for cancer chemotherapy since the subject was last discussed in this journal in 1997, with the exception of fields that have been subsequently covered by other more focused reviews in the same journal.In particular we will summarise developments in the design and biochemical and pharmacological evaluation of novel antineoplastic agents belonging to the following classes: natural and fermentation products, DNA-targeted cytotoxic compounds, drugs for photodynamic therapy, non-taxane antimicrotubule agents, apoptosis modulators, enzymatic inhibitors, hormonal agents, multi-drug resistance reverters and antimetastatic drugs.
引用
收藏
页码：1627 / 1672
页数：46
相关论文
共 79 条
[1]   Cancer research - Designing therapies that target tumor blood vessels [J].
Barinaga, M .
SCIENCE, 1997, 275 (5299) :482-484
[2]   Chromosomal translocations involving paired box transcription factors in human cancer [J].
Barr, FG .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (12) :1449-1461
[3]   Matrix metalloproteinase inhibitors 1998 [J].
Beckett, RP ;
Whittaker, M .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) :259-282
[4]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[5]  
Bridewell DJA, 1997, ONCOL RES, V9, P535
[6]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276
[7]  
Buzdar AU, 1998, CLIN CANCER RES, V4, P527
[8]   Protein kinase C: A worthwhile target for anticancer drugs? [J].
Caponigro, F ;
French, RC ;
Kaye, SB .
ANTI-CANCER DRUGS, 1997, 8 (01) :26-33
[9]   PP60C-SRC ACTIVATION IN HUMAN-COLON CARCINOMA [J].
CARTWRIGHT, CA ;
KAMPS, MP ;
MEISLER, AI ;
PIPAS, JM ;
ECKHART, W .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) :2025-2033
[10]   Expression, subcellular distribution and response to phorbol esters of protein kinase C (PKC) isozymes in drug-sensitive and multidrug-resistant KB cells - Evidence for altered regulation of PKC-alpha [J].
CloudHeflin, BA ;
McMasters, RA ;
Osborn, HT ;
Chambers, TC .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 239 (03) :796-804
12345678